Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. Published
  2. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Jun 2003.

    Research output: Contribution to conferencePaper

  3. Published

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Feb 2005, In: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, p. 29-38

    Research output: Contribution to journalArticlepeer-review

  4. Published

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Nov 2007, In: Value in Health. 10, 6, p. 498-509

    Research output: Contribution to journalArticlepeer-review

  5. Published

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346

    Research output: Contribution to journalArticlepeer-review

  6. Published

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Aug 2010, In: Value in Health. 13, 5, p. 675-680

    Research output: Contribution to journalArticlepeer-review

  7. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conferencePaper

  8. Published

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Dec 2007.

    Research output: Contribution to conferencePaper

  9. Published

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Sept 2003.

    Research output: Contribution to conferencePaper

  10. Published
  11. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conferencePaper

  12. Published

    Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.

    Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 May 2009, In: Pharmacoeconomics. 27, 8, p. 635-643

    Research output: Contribution to journalArticlepeer-review

  13. Published

    Management of Patients Symptomatically Unresponsive to Levothyroxine: Natural Desiccated Thyroid Extract or the Combination of Levothyroxine and Liothyronine? A Research Priority

    Hughes, D., Livingston, M. & Heald, A., Sept 2020, In: Experimental and Clinical Endocrinology & Diabetes . 128, 9, p. 596-598

    Research output: Contribution to journalLetterpeer-review

  14. Published

    Economics of pharmacogenetic guided treatments: Underwhelming or overstated?

    Hughes, D., May 2018, In: Clinical Pharmacology and Therapeutics. 103, 5, p. 749-751

    Research output: Contribution to journalArticlepeer-review

  15. Published

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059

    Research output: Contribution to journalArticlepeer-review

  16. Published

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 3, p. 211-213

    Research output: Contribution to journalArticlepeer-review

  17. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  18. Published

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554

    Research output: Contribution to journalArticlepeer-review

  19. Published

    Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population

    Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Jul 2014, In: Epilepsy and Behavior. 36, p. 12-17

    Research output: Contribution to journalArticlepeer-review

  20. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  21. Published

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.

    Research output: Contribution to conferencePaper

  22. Published

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conferencePaper

  23. Published

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836

    Research output: Contribution to journalArticlepeer-review

  24. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conferencePaper

  25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  26. Published

    Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group

    Hughes, D., Linck, P. G., Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P. & Cowell, W., 1 Dec 2013, In: Osteoporosis International. 24, 12, p. 2907-2918

    Research output: Contribution to journalArticlepeer-review

  27. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jul 2005.

    Research output: Contribution to conferencePaper

  28. Published

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/ReportCommissioned report

  29. Published
  30. Published

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.

    Research output: Contribution to conferencePaper

  31. Published

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 4, p. 315-316

    Research output: Contribution to journalArticlepeer-review

  32. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Mar 2010, In: Clinical Pharmacology and Therapeutics. 87, 3, p. 257-261

    Research output: Contribution to journalArticlepeer-review

  33. Published
  34. Published

    Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios

    Hughes, D., Parham, P. E. & Hughes, D. A., 16 Feb 2015, In: Philosophical Transactions B: Biological Sciences. 370, 1665

    Research output: Contribution to journalArticlepeer-review

  35. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  36. Published

    The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors

    Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Jan 2012, In: British Journal of Clinical Pharmacology. 73, 1, p. 66-76

    Research output: Contribution to journalArticlepeer-review

  37. Published

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351

    Research output: Contribution to journalArticlepeer-review

  38. Published

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  39. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  40. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journalArticlepeer-review

  41. Published

    Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

    Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Dec 2012, In: Value in Health. 15, 8, p. 1162-1171

    Research output: Contribution to journalArticlepeer-review

  42. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conferencePaper

  43. Published

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.

    Research output: Book/ReportCommissioned report

  44. Published

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Jan 2008, In: Value in Health. 11, 4, p. 600-610

    Research output: Contribution to journalArticlepeer-review

  45. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

    Research output: Contribution to journalArticlepeer-review

  46. Published

    Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

    Hughes, D., Linley, W. G. & Hughes, D. A., 1 Apr 2013, In: Pharmacoeconomics. 31, 4, p. 345-355

    Research output: Contribution to journalArticlepeer-review

  47. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conferencePaper

  48. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  49. Published

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Jan 2013, In: Nature Reviews Drug Discovery. 12, 3-4

    Research output: Contribution to journalArticlepeer-review

  50. Published

    Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group

    Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Lal, L., Salas, M., Hughes, D. A., Ratzki-Leewing, A. & Grubisic, M., 1 Jul 2013, In: Value in Health. 16, 5, p. 863-871

    Research output: Contribution to journalArticlepeer-review